Mechanisms of Contact Sensitization Offer Insights into the Role of Barrier Defects vs. Intrinsic Immune Abnormalities as Drivers of Atopic Dermatitis  by Dhingra, Nikhil et al.
Ridker PM, Rifai N et al. (2007) Development and
validation of improved algorithms for the
assessment of global cardiovascular risk in
women: the Reynolds Risk Score. JAMA
297:611–9
Samarasekera EJ, Neilson JM, Warren RB et al.
(2013) Incidence of cardiovascular disease
in people with psoriasis: a systematic review
and meta-analysis. J Invest Dermatol 133:
2340–6
Wakkee M, Herings RM, Nijsten T (2010)
Psoriasis may not be an independent risk
factor for acute ischemic heart disease hospi-
talizations: results of a large population-
based Dutch cohort. J Invest Dermatol 130:
962–7
Wang Y, Gao H, Loyd CM et al. (2012) Chronic
skin-specific inflammation promotes vascular
inflammation and thrombosis. J Invest
Dermatol 132:2067–75
Mechanisms of Contact Sensitization
Offer Insights into the Role of Barrier
Defects vs. Intrinsic Immune
Abnormalities as Drivers of Atopic
Dermatitis
Nikhil Dhingra1,2, Nicholas Gulati1 and Emma Guttman-Yassky1,3
Atopic dermatitis (AD) is a common inflammatory skin disease characterized by wet,
oozing, erythematous, pruritic lesions in the acute stage and xerotic, lichenified
plaques in the chronic stage. It frequently coexists with asthma and allergic rhinitis,
sharing some mechanistic features with these diseases as part of the ‘‘atopic march.’’
Controversy exists as to whether immune abnormalities, epidermal barrier defects,
or both are the primary factors responsible for disease pathogenesis. In AD patients,
there is often a coexisting irritant contact dermatitis (ICD) or allergic contact
dermatitis (ACD) that is sometimes clinically difficult to distinguish from AD. ACD
shares molecular mechanisms with AD, including increased cellular infiltrates and
cytokine activation (Gittler et al., 2013). In this issue, Newell et al. (2013) used an
experimental contact sensitization model with dinitrochlorobenzene (DNCB) to gain
insight into the unique immune phenotype of AD patients.
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Epidermal barrier defects characterize
lesional and nonlesional AD skin
The stratum corneum, including terminal
differentiation proteins such as filaggrin
(FLG), corneodesmosin, and loricrin, is a
first-line defense against irritants and
allergens. The genomic expression of
key barrier molecules, which comprise
the epidermal differentiation complex on
chromosome 1q21, have been pre-
viously shown to be downregulated in
AD patients in both lesional and nonle-
sional skin (Sua´rez-Farin˜as et al., 2011).
Furthermore, frequent mutations in the
FLG gene (found in up to 30–50% of AD
patients) have been associated with the
severity of AD (as identified by the
Scoring of AD (SCORAD) index). These
differentiation abnormalities contribute
to the barrier defect in AD, ultimately
resulting in increased transepidermal
water loss, xerosis, and greater penetra-
tion of various agents (Gittler et al.,
2013). In humans, FLG deficiency has
been linked to increased risk of the other
atopic diseases, as well as to greater
See related article on pg 2372
susceptibility to common triggers of AD
(including allergens and microbes).
Murine models with reduced FLG ex-
hibit greater passive transfer of protein
allergens and reduced thresholds to irri-
tants (Irvine et al., 2011). These studies
provide the basis for the ‘‘outside-in’’
hypothesis of AD, which states that
transfer of external triggers across a dys-
functional barrier elicits the disease’s
characteristic immune responses.
Although FLG and other defects in the
barrier have been linked to AD
pathogenesis, there are notable limita-
tions to this hypothesis. For example, an
inverse correlation has been established
between the expression levels of several
terminal differentiation molecules and
AD disease severity (as measured by the
SCORAD index) (Sua´rez-Farin˜as et al.,
2011). This raises the possibility of a
reactive epidermal barrier to a primary
immune insult. Furthermore, impressive
reductions in key terminal differentia-
tion molecules, extending far beyond
FLG, have been found even in non-
lesional AD skin. In addition, a
majority of AD patients do not harbor
FLG mutations, and even those with
them have been shown to outgrow the
disease (Guttman-Yassky et al., 2011).
Collectively, these observations suggest
that barrier dysfunction is not the sole
contributor to disease pathogenesis.
AD is primarily Th2 and Th22 polarized
The historical immune paradigm for
AD characterized it largely as a
T helper type 2 (Th2)-mediated disease
with high levels of IL-4, IL-13, and
Th2-polarizing chemokines (i.e.,
CCL17, CCL18, and CCL22). Recent
work has implicated additional key
Th2-associated cytokines and factors,
including IL-31, thymic stromal lympho-
poietin (TSLP), and OX40. Th2 signaling
has been demonstrated to produce
many of the molecular findings seen in
AD skin, with the exception of the
characteristic epidermal hyperplasia.
Allergen-specific Th2 T cells can be
found in AD but not in nonatopic con-
trols (Ardern-Jones et al., 2007). More
recently, Th22 T cells and their
cytokine, IL-22, have been shown to
have a key role in the pathogenesis of
AD, potentially accounting for the incre-
ased epidermal thickness. Langerhans
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cells (LCs) and/or CD11cþ dermal
dendritic cells (dDCs), which are up-
regulated in AD, have been associated
with both Th2 and Th22 polarization,
possibly explaining the predominance
of these T-cell subsets in the disease
(Fujita et al., 2011; Gittler et al., 2013).
AD has also been shown to have a Th1
component in the chronic phase, and a
Th17 component in the acute stage
(Guttman-Yassky et al., 2011; Gittler
et al., 2013). Thus, concepts of the AD
immune phenotype have become incre-
asingly complex, with evidence for
activation of several pathways beyond
the Th2 axis (Figure 1a). Recently, the
‘‘background’’ or nonlesional disease
phenotype has also been shown to dis-
play increased cellular infiltrates (i.e., T
cells, DCs, and LCs), as well as increased
expression of inflammatory mediators,
compared with normal skin (Sua´rez-
Farin˜as et al., 2011), possibly influe-
nced by systemic cytokine activation
and genetic or environmental factors
that remain to be identified.
The interplay between barrier defects and
immune abnormalities
In addition to its role as a physical
barrier, the epidermis contributes to
inflammatory responses. Keratinocytes
(KCs) in AD are key producers of TSLP,
which acts via OX40L on dDCs to
polarize T cells toward a Th2 phenotype
(Gittler et al., 2013). Th2 cytokines IL-4,
IL-13, and IL-31, along with Th22-
derived IL-22, have been demonstrated
to suppress terminal differentiation
molecules (i.e., FLG and LOR),
ultimately disrupting barrier function
(Figure 1a). These findings led to the
‘‘inside-out’’ hypothesis of AD, suggest-
ing that the epidermal changes are
reactions to Th2 and Th22 signaling
(Guttman-Yassky et al., 2011). Recent
studies have shown that the barrier and
immune defects are interactive players
in the pathogenesis of AD (Gittler et al.,
2013). Moreover, immune activation
through epicutaneous antigen exposure
is an important mechanism that per-
petuates the inflammation and immune-
driven epidermal changes that charac-
terize AD. Understanding the mecha-
nisms of immune sensitization to
topical antigens in AD patients may
help us understand the factors that
participate in disease onset.
New insights into AD pathogenesis
obtained through contact sensitization
Molecules such as DNCB and other
haptens provide a useful model for
epicutaneous allergen exposure through
intact or disturbed skin. Newell et al.
(2013) elegantly showed equivalent
penetration of DNCB, an almost univer-
sally sensitizing epicutaneous allergen,
in AD patients, regardless of FLG muta-
tion status. Through sensitization with
DNCB, they showed Th2 polarization
and attenuated hypersensitivity reactions
in nonlesional AD skin compared with
skin from healthy volunteers. Their data
show that the unique immune pheno-
type of AD patients is perpetuated by
allergen challenge regardless of muta-
tion status.
Several important questions remain
unanswered about contact sensitization
in atopic individuals. Although DNCB
provides an excellent experimental
model for studying contact hypersensi-
tivity, it is not an allergen that leads to
ACD in a clinical setting. Penetration of
‘‘true’’ allergens that typically affect
allergic individuals, such as nickel and
rubber accelerators, may be more influ-
enced by barrier defects and a patient’s
genetic background than DNCB.
Although Newell et al. (2013) demon-
strated that background immune abnor-
malities in AD skin contribute to the
distinct Th2 polarization upon DNCB
challenge, their approach does not
address whether this holds true for
commonly encountered allergens.
Furthermore, compared with the
almost universal potential for sensiti-
zation of DNCB, clinically relevant
allergens affect different individuals
with varying degrees of severity, and
therefore immune differences among
AD patients might influence allergen
reactivity. In addition, both ACD and
ICD are more common in AD patients.
Although ACD is a delayed-type hyper-
sensitivity reaction relying on antigen
presentation in sensitized individuals, it
has been suggested that ICD (Figure 1b)
is a prerequisite for ACD (Figure 1c)
(Bonneville et al., 2007). ICD, which
occurs via activation of innate immunity
by KCs upon exposure to toxic irritants,
may decrease the threshold for gene-
rating ACD reactions. This threshold
may be decreased further in AD patients
with defective barriers, increasing
overall rates of allergen sensitization.
However, despite the increased preva-
lence of allergic responses in AD, the
resulting immune reactions are attenua-
ted in these patients as compared with
controls. This hyporesponsiveness may
possibly be explained by altered LC or
dDC function or differences in T-cell
subsets in AD patients compared with
nonatopic individuals.
Although it remains unclear where
the primary abnormality lies in skewing
T cells toward a Th2 phenotype in AD,
insight is provided by DNCB-induced
Th2 polarization through nonlesional
AD skin, which we previously charac-
terized with barrier and immune
defects. Collectively, these concepts
suggest that increased antigen penetra-
tion and/or altered antigen-presenting
cell function in nonlesional AD
skin result in an initial Th2-polarized
response that can amplify over time into
clinically inflamed lesions. The finding
of Newell et al. (2013) that ACD in the
context of AD is immunologically dis-
tinct, showing a Th2 rather than the con-
ventional Th1 polarization, highlights
the central role of the Th2 pathway in
disease pathogenesis. In fact, emerging
studies targeting IL-4R in AD patients
show promising initial results (Simpson,
2013), supporting the pathogenic role of
Clinical Implications
 Atopic dermatitis (AD) is T helper type 2 (Th2)-polarized and often co-
occurs with contact dermatitis.
 Using contact sensitization, Newell et al. provide insights into the Th2
skewing of AD.
 Th2 skewing is independent of filaggrin status.
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Th2. Future studies are needed to
address the role of allergic sensitization
to common allergens in programming
the AD immune phenotype.
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Figure 1. Immune mechanism in the pathogenesis of atopic dermatitis (AD), irritant contact dermatitis (ICD), and allergic contact dermatitis (ACD). (a) In
patients with AD, a disturbed epidermal barrier leads to increased permeation of antigens, which encounter Langerhans cells (LCs), inflammatory dendritic
epidermal cells (iDECs), and dermal dendritic cells (dDCs), activating T helper type 2 (Th2) T cells to produce IL-4 and IL-13. Dendritic cells (DCs) then travel
to lymph nodes, where they activate effector T cells and induce IgE class switching. IL-4 and IL-13 stimulate keratinocytes (KCs) to produce thymic stromal
lymphopoietin (TSLP). TSLP activates OX40 ligand–expressing dDCs to induce inflammatory Th2 T cells. Cytokines and chemokines, such as IL-4, IL-5, IL-13,
eotaxins, CCL17, CCL18, and CCL22, produced by Th2 T cells and DCs stimulate skin infiltration by DCs, mast cells, and eosinophils (EOS). Th2 and Th22 T cells
predominate in patients with AD, but Th1 and Th17 T cells also contribute to its pathogenesis. The Th2 and Th22 cytokines (IL-4/IL-13 and IL-22, respectively)
were shown to inhibit terminal differentiation and contribute to the barrier defect in patients with AD. Thus, both the barrier defects and immune activation alter
the threshold for ICD, ACD, and self-reactivity in patients with AD. TEWL, transepidermal water loss. (b) In patients with ICD, exposure to an irritant exerts toxic
effects on KCs, activating innate immunity with the release of IL-1a, IL-1b, tumor necrosis factor (TNF)-a, GM-CSF, and IL-8 from epidermal KCs. In turn, these
cytokines activate LCs, dDCs, and endothelial cells, all of which contribute to cellular recruitment to the site of KC damage. Infiltrating cells include neutrophils,
lymphocytes, macrophages, and mast cells, which further promote an inflammatory cascade. (c) In the sensitization phase of ACD, similar to ICD, allergens
activate innate immunity through KC release of IL-1a, IL-1b, TNF-a, GM-CSF, IL-8, and IL-18, inducing vasodilation, cellular recruitment, and infiltration. LCs and
dDCs encounter the allergen and migrate to the draining lymph nodes, where they activate hapten-specific T cells, which include Th1, Th2, Th17, and regulatory T
(Treg) cells. These T cells proliferate and enter the circulation and site of initial exposure, along with mast cells and EOS. On re-encountering the allergen, the
elicitation phase occurs, in which the hapten-specific T cells, along with other inflammatory cells, enter the site of exposure and, through release of cytokines and
consequent stimulation of KCs, induce an inflammatory cascade. MBP, major basic protein; TGF-b, transforming growth factor-b. Reprinted from Gittler et al.
(2013), with permission from Elsevier.
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Glucocorticoids in Autoimmune
Bullous Diseases: Are Neutrophils
the Key Cellular Target?
Dagmar Simon1, Luca Borradori1 and Hans-Uwe Simon2
The newly observed nongenomic effects of glucocorticoids on signaling pathways
operating in neutrophils in vitro will stimulate further investigations on pathogenic
mechanisms and drug actions in bullous skin diseases.
Journal of Investigative Dermatology (2013) 133, 2314–2315. doi:10.1038/jid.2013.205
There is by far no other drug class that is
used so frequently by dermatologists
as glucocorticoids. Their use as either
topical or systemic anti-inflammatory
drugs is based on their ability to block
the expression of proinflammatory genes
and to induce the transcription of anti-
inflammatory genes (Rhen and Cidlowski,
2005). Besides these transcription-
dependent mechanisms, glucocorti-
coids can have rapid effects on
inflammation that are not mediated
by changes in gene expression. For
instance, the inhibition of vasodila-
tion and reduction in endothelial
permeability are believed to contribute
to the anti-inflammatory activity of
glucocorticoids (Rhen and Cidlowski,
2005). Other nontranscriptional mecha-
nisms may include decreased stability of
mRNAs of cytokine genes (Gille et al.,
2001). Furthermore, the activation of
caspases by glucocorticoids in eosino-
phils, but not neutrophils, has been
described (Meagher et al.,1996). There
is, however, little information regarding
the molecular mechanisms of these so-
called nongenomic pathways available.
Bullous pemphigoid (BP) represents
the most frequent autoimmune sub-
epidermal blistering disease, character-
istically associated with autoantibodies
directed against BP180 (also termed
BPAG2) and BP230 (BPAG1-e), two
components of junctional adhesion
complexes called hemidesmosomes
(Borradori and Sonnenberg, 1999).
Besides these autoantibodies, neutro-
phils have been shown to have a
critical role in BP (Liu et al., 1997).
In this issue of the Journal, Hellberg
et al. (2013) investigated the effects
of methylprednisolone on human
neutrophils as BP can be efficiently
treated with either topical or systemic
glucocorticoids (Joly et al., 2002).
The authors hypothesized that methy-
lprednisolone might directly block
neutrophil activation here (Figure 1).
Intriguingly, they observed in fact a
marked block of autoantibody-induced
activation of phosphatidylinositide
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3-kinase (PI3K), p38 mitogen-activated
protein kinase (MAPK), and extracellular
signal–regulated kinases 1/2 (ERK1/2)
in purified human neutrophils in vitro.
As these findings are provocative, the
authors have additionally demonstrated
that methylprednisolone, as well as
more or less specific inhibition of these
kinases by known pharmacological
inhibitors, could block the production
of reactive oxygen species (ROS) in acti-
vated neutrophils. Methylprednisolone
and the kinase inhibitors were also able
to prevent blister formation in both
ex vivo and in vivo BP models.
The activation of the nicotinamide
adenine dinucleotide phosphate
(NADPH) oxidase, the enzyme largely
responsible for ROS production in
neutrophils, has previously been shown
to require activation of pathways invol-
ving p38 and PI3K (Geering et al.,
2011). If methylprednisolone is indeed
able to pharmacologically inacti-
vate these kinases, under the in vitro
conditions used by the authors, it is
not surprising that it also blocks ROS
production by activated neutrophils.
It is, however, less clear that
neutrophil-derived ROS are required
for blister formation in BP. Moreover, it
should be noted that these authors used
whole leukocyte populations for their
ex vivo model. Therefore, it is unclear
whether the observed epidermal–dermal
separation was indeed mediated selec-
tively by neutrophils. The situation
in vivo is even more complex; it is
uncertain whether a potential inhibition
of PI3K, p38 MAPK, or ERK1/2 in
neutrophils is indeed the main effect
responsible for the prevention of blister
formation. In addition, it should be
noted that with these in vivo models
all inhibitors were given in a prophylac-
tic and not in a therapeutic manner,
suggesting that the initiation of the
inflammatory cascade was blocked,
including neutrophil infiltration.
Similarly, the question whether methyl-
prednisolone could reduce kinase acti-
vation of already-activated neutrophils
remains to be answered.
Besides these fundamental questions,
which need to be answered in future
studies, an additional note of caution
ought to be raised. The authors used
extremely high methylprednisolone
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